CX-2029

N/A

Report date: 2022/11/25 17:01:22

Base Information

Drug NameCX-2029
Drug Alias NameCD71 PDCCD71 probody drug conjugate - CytomX TherapeuticsCX-2029ABBV-2029ABBV-CX-2029
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTransferrin receptor protein 1 antagonists
TargetsTransferrin receptor protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCytomx Therapeutics IncAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytomx Therapeutics IncAbbvie Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A